Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
Overview
Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. It is headquartered in Bresso near Milan, Italy, with R&D operations in its Basel, CH, subsidiary.
The Company currently has two late stage product candidates in development and a pipeline of earlier compounds.
Newron is undertaking phase III trials of its lead candidate, safinamide, for the treatment of Parkinson's disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer's disease, and other therapeutic applications.
Newron recently initiated a potentially pivotal study (SERENA) with ralfinamide in patients with neuropathic low back pain (NLBP). There are no approved drugs for the treatment of NLBP, an indication experienced by about 55m patients in the USA, Europe and Japan.
Newron's additional projects are in development at various stages of preclinical and clinical development, including NW3509 which, like ralfinamide, is a project from Newron's ion channel research.